Poor
Not Aligned
Patient Risk:
Medium
Summary
Only the mechanism-of-action statements are supported by the provided FDA label excerpts. Most other claims (indications, manufacturer/approval date, DOAC class examples, and specific patient bleeding sign examples) are unsupported or unverified against the supplied label text, resulting in poor overall alignment.
Category Scores
Accurate Statements
Edoxaban functions by inhibiting Factor Xa.
Supported by label excerpts: 11 DESCRIPTION; 12.1 Mechanism of Action
By blocking Factor Xa, edoxaban reduces thrombin generation.
Supported by label excerpts: 12.1 Mechanism of Action
Reducing thrombin generation prevents the formation of blood clots.
Supported by label excerpts: 12.1 Mechanism of Action
Major bleeding from Savaysa can be life-threatening.
Supported by label excerpt: 5.3 Risk of Bleeding (serious and potentially fatal bleeding)
Unsupported Statements
The manufacturer of Savaysa (edoxaban) is Daiichi Sankyo.
Not supported by the provided label excerpts (no label reference available).
Savaysa (edoxaban) is used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation.
The provided label excerpts do not include the relevant indication wording; label support is not established from the supplied text.
Savaysa (edoxaban) is used to treat deep vein thrombosis (DVT).
The provided label excerpts do not include DVT treatment indication wording; label support is not established from the supplied text.
Savaysa (edoxaban) is used to treat pulmonary embolism (PE).
The provided label excerpts do not include PE treatment indication wording; label support is not established from the supplied text.
Savaysa (edoxaban) is used to prevent deep vein thrombosis (DVT).
The provided label excerpts do not include DVT prevention indication wording; label support is not established from the supplied text.
Savaysa (edoxaban) is used to prevent pulmonary embolism (PE).
The provided label excerpts do not include PE prevention indication wording; label support is not established from the supplied text.
Edoxaban received approval from the U.S. Food and Drug Administration (FDA) in December 2014.
Not supported by the provided label excerpts.
Common side effects of Savaysa include bruising.
No bruising as a common side effect is supported by the provided excerpts.
Common side effects of Savaysa include nausea.
No nausea as a common side effect is supported by the provided excerpts.
Patients should be aware of signs of bleeding such as unusual bruising.
No specific bleeding-sign examples are supported in the provided excerpts.
Patients should be aware of signs of bleeding such as prolonged bleeding from cuts.
No specific bleeding-sign examples are supported in the provided excerpts.
Patients should be aware of signs of bleeding such as nosebleeds.
No specific bleeding-sign examples are supported in the provided excerpts.
Patients should be aware of signs of bleeding such as bleeding gums.
No specific bleeding-sign examples are supported in the provided excerpts.
Patients should be aware of signs of bleeding such as blood in urine.
No specific bleeding-sign examples are supported in the provided excerpts.
Patients should be aware of signs of bleeding such as blood in stool.
No specific bleeding-sign examples are supported in the provided excerpts.
Edoxaban is a direct oral anticoagulant (DOAC).
Not supported by the provided label excerpts.
DOACs include apixaban (Eliquis).
Not supported by the provided label excerpts.
DOACs include rivaroxaban (Xarelto).
Not supported by the provided label excerpts.
DOACs include dabigatran (Pradaxa).
Not supported by the provided label excerpts.
Compared with older anticoagulants like warfarin, DOACs offer predictable dosing regimens.
Not supported by the provided label excerpts.
Compared with older anticoagulants like warfarin, DOACs have less need for routine blood monitoring.
Not supported by the provided label excerpts.
Comparisons between specific DOACs often focus on efficacy in different patient populations.
Not supported by the provided label excerpts.
Comparisons between specific DOACs often focus on bleeding risk profiles.
Not supported by the provided label excerpts.
Comparisons between specific DOACs often focus on drug-drug interaction potential.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
Dosage and administration details (dose, frequency, renal adjustment, missed dose, and administration instructions) were not provided, so label-alignment for dosing cannot be evaluated.
Importance:
High
Contraindications and risk/management statements beyond bleeding (e.g., active pathological bleeding specifics are present in excerpts, but no claims address them) were not evaluated due to no relevant claims being made.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Unsupported claims about indications and specific bleeding-sign counseling could mislead about appropriate use and patient monitoring/counseling; mechanism-of-action accuracy is present but does not offset the high proportion of unsupported clinical and counseling claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most clinical and counseling claims are unsupported by the provided FDA label excerpts.
Suggested Improvement
Restrict statements to label-supported content from the provided sections (e.g., 12.1 mechanism; 5.3 bleeding risk language) and remove or properly source indication, class/peer drug examples, approval date/manufacturer claims, and specific bleeding-sign examples unless supported by the supplied label text.